Embodied dual-arm design
CASIVIBOT uses dual arms and a hand-eye-brain architecture for flexible work on industrial lines, according to launch coverage. [1]
Price & availability
Available to order from Jun 2026
Current dataset status: Commercial.
Product overview
CASIVIBOT is a wheeled, dual-arm embodied robot made by CASIVISION (中科慧远), a Chinese company that builds automated optical inspection equipment. CASIVISION launched the robot on 19 August 2025 for industrial quality inspection.
The robot pairs a multispectral camera system, built from three camera groups, with two cooperating arms. Launch coverage gives 360-degree bottle inspection as one application. At WAIC 2026 the company described the platform as using a vision-language model for few-shot detection and said new product types can be taught within 24 hours; these are company claims rather than independent test results.
On 16 June 2026 CASIVISION held a batch roll-off and delivery event. The Luoyang municipal government reported that the robot had entered small-batch production and was being used in four inspection scenarios: automotive motor stators, hard-alloy blades, precision cutting tools and packaging products. It also said shipments were expected to exceed 100 units in 2026. This evidence supports commercial status, although the maker has not published an order page or price.
No authoritative dimensions, payload, runtime or battery capacity were found, so those fields remain empty.
Capabilities
CASIVIBOT uses dual arms and a hand-eye-brain architecture for flexible work on industrial lines, according to launch coverage. [1]
The launch coverage describes a multispectral system that supports wide-field scanning and micron-level inspection. [1]
The company says new product types can be taught and delivered within 24 hours, a claim it made at WAIC 2026. [3]
Hardware profile
Quick answers
Side by side
Choose up to four robots for a sourced specification and price comparison.
Evaluation footprint
No benchmark embodiments or results reference this robot yet.
Related
Evidence